These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34295147)

  • 1. Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration.
    Apsangikar P; Ghadge P; Naik M; Nair S; Payghan R
    Clin Ophthalmol; 2021; 15():3087-3095. PubMed ID: 34295147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis
    Singh R; Chauhan R; Saxena A; Shah A; Mondal L; Bakhle D; Shah C; Shah A; Deoghare S; Krishnan N; Godse N
    Indian J Ophthalmol; 2022 Aug; 70(8):3008-3014. PubMed ID: 35918962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
    Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
    Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.
    Ghosh AK; Nikumbh US; Shukla CK; Laul RS; Dixit A; Mahapatra SK; Nayak S; Shah UM; Parwal S; Venkatapathy N; Radhakrishnan N; Kelgaonkar A; Saxena S; Mishra D; Dave VP; Khan P; Saswade MR; Shantilal MS; Ramasamy K; Sreekanta S; Rajurkar M; Doshi M; Behera S; Patel P; Dhawan S; Lakhwani L
    Ophthalmol Ther; 2024 May; 13(5):1369-1382. PubMed ID: 38530568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Loewenstein A; Czumbel N; Ernest J; Dusová J; Pearlman J; Nowosielska A
    Ophthalmol Retina; 2023 Sep; 7(9):753-761. PubMed ID: 37179017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
    JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
    Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
    Apsangikar P; Ghadge P; Naik M; Nair S
    J Assoc Physicians India; 2020 Dec; 68(12):61-65. PubMed ID: 33247645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.
    Khurana RN; Kunimoto D; Yoon YH; Wykoff CC; Chang A; Maturi RK; Agostini H; Souied E; Chow DR; Lotery AJ; Ohji M; Bandello F; Belfort R; Li XY; Jiao J; Le G; Kim K; Schmidt W; Hashad Y;
    Ophthalmology; 2021 Jul; 128(7):1027-1038. PubMed ID: 33221326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C;
    Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
    Kunimoto D; Yoon YH; Wykoff CC; Chang A; Khurana RN; Maturi RK; Agostini H; Souied E; Chow DR; Lotery AJ; Ohji M; Bandello F; Belfort R; Li XY; Jiao J; Le G; Schmidt W; Hashad Y;
    Ophthalmology; 2020 Oct; 127(10):1331-1344. PubMed ID: 32471729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
    Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.